CureVac (NASDAQ:CVAC - Get Free Report)'s stock price gapped up prior to trading on Monday . The stock had previously closed at $4.47, but opened at $4.66. CureVac shares last traded at $4.68, with a volume of 251,500 shares traded.
Analyst Upgrades and Downgrades
Several brokerages have commented on CVAC. JMP Securities reiterated a "market outperform" rating and set a $10.00 price target on shares of CureVac in a report on Wednesday, May 28th. UBS Group lowered their price target on CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th.
Get Our Latest Research Report on CureVac
CureVac Stock Performance
The stock has a market capitalization of $1.00 billion, a P/E ratio of 8.11 and a beta of 2.49. The firm has a 50-day moving average of $3.49 and a 200 day moving average of $3.38. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.
CureVac (NASDAQ:CVAC - Get Free Report) last issued its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The company had revenue of $0.94 million for the quarter, compared to the consensus estimate of $4.27 million. Research analysts anticipate that CureVac will post 0.72 EPS for the current fiscal year.
Institutional Trading of CureVac
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CVAC. GSA Capital Partners LLP acquired a new position in shares of CureVac in the 1st quarter valued at approximately $853,000. BNP Paribas Financial Markets bought a new stake in CureVac in the 4th quarter valued at $585,000. Millennium Management LLC raised its stake in CureVac by 10.3% in the 1st quarter. Millennium Management LLC now owns 1,816,984 shares of the company's stock valued at $5,033,000 after acquiring an additional 169,947 shares during the period. Two Sigma Investments LP bought a new stake in CureVac in the 4th quarter valued at $391,000. Finally, State of Wyoming acquired a new position in CureVac in the 1st quarter valued at $317,000. 17.26% of the stock is currently owned by institutional investors and hedge funds.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Further Reading
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
